📣 VC round data is live. Check it out!
- Public Comps
- Selvita
Selvita Valuation Multiples
Discover revenue and EBITDA valuation multiples for Selvita and similar public comparables like Euroapi, Genovis, Lifecore Biomedical, Savior Lifetec and more.
Selvita Overview
About Selvita
Selvita SA is a Poland based parent company of Selvita Group is one of the largest preclinical contract research organizations in Europe. It also develops bioinformatics solutions supporting innovative projects at preclinical stages. It also provides services provided to external contractors are in the field of chemistry, analytics, regulatory, biochemistry and cell biology and also the integrated research and development projects.
Founded
2007
HQ

Employees
969
Website
Financials (LTM)
EV
$201M
Valuation Multiples
Start free trialSelvita Financials
Selvita reported last 12-month revenue of $104M and EBITDA of $20M.
In the same LTM period, Selvita generated $20M in EBITDA and $2M in net income.
Revenue (LTM)
Selvita P&L
In the most recent fiscal year, Selvita reported revenue of $101M and EBITDA of $19M.
Selvita is profitable as of last fiscal year, with gross margin of 81%, EBITDA margin of 18%, and net margin of 0%.
Financial data powered by Morningstar, Inc.
Selvita Stock Performance
Selvita has current market cap of $161M, and enterprise value of $201M.
Market Cap Evolution
Selvita's stock price is $8.76.
Selvita share price decreased by 8.8% in the last 30 days, and increased by 7.1% in the last year.
Selvita has an EPS (earnings per share) of $0.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $201M | $161M | -1.6% | -8.8% | -27.1% | 7.1% | $0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSelvita Valuation Multiples
Selvita trades at 1.9x EV/Revenue multiple, and 10.0x EV/EBITDA.
EV / Revenue (LTM)
Selvita Financial Valuation Multiples
As of May 9, 2026, Selvita has market cap of $161M and EV of $201M.
Selvita has a P/E ratio of 80.2x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Selvita Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Selvita Margins & Growth Rates
Selvita grew revenue by 9% and EBITDA by 24% in the last fiscal year.
In the most recent fiscal year, Selvita reported gross margin of 81%, EBITDA margin of 18%, and net margin of 0%.
Selvita Margins
Selvita Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Selvita Operational KPIs
Selvita's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Selvita's Rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Selvita's Rule of X is 44% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Selvita Competitors
Selvita competitors include Euroapi, Genovis, Lifecore Biomedical, Savior Lifetec, Mycenax Biotech, Prestige Biologics, Binex, Champions Oncology, Frontage Laboratories and Nanoform.
Most Selvita public comparables operate across Contract Research & Manufacturing, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.1x | 0.1x | 8.9x | 1.4x | |||
| 9.2x | 9.0x | 29.0x | 32.0x | |||
| 2.4x | 3.2x | 23.4x | 18.2x | |||
| 3.7x | — | 7.0x | — | |||
| 9.1x | — | (49.7x) | — | |||
| 20.0x | — | (44.3x) | — | |||
| 2.5x | 2.4x | 32.7x | 79.0x | |||
| 1.4x | — | 11.2x | — | |||
This data is available for Pro users. Sign up to see all Selvita competitors and their valuation data. Start Free Trial | ||||||
Selvita M&A Activity
Selvita has acquired 1 company to date.
Last acquisition by Selvita was on March 27th 2024. Selvita acquired PozLab for $6M (EV/Revenue multiple of ).
Latest Acquisitions by Selvita
| Description | PozLab is a Poznań-based laboratory offering analytical and R&D services for pharmaceutical, food, cosmetic, and veterinary sectors in Poland. The firm develops formulations for drugs, dietary supplements, and cosmetics from initial concept through regulatory approval and market launch. |
| HQ Country | |
| HQ City | Poznan |
| Deal Date | 27 Mar 2024 |
| Valuation | $6M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Selvita acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Selvita
| When was Selvita founded? | Selvita was founded in 2007. |
| Where is Selvita headquartered? | Selvita is headquartered in Poland. |
| How many employees does Selvita have? | As of today, Selvita has over 969 employees. |
| Is Selvita publicly listed? | Yes, Selvita is a public company listed on Warsaw Stock Exchange. |
| What is the stock symbol of Selvita? | Selvita trades under SLV ticker. |
| When did Selvita go public? | Selvita went public in 2019. |
| Who are competitors of Selvita? | Selvita main competitors include Euroapi, Genovis, Lifecore Biomedical, Savior Lifetec, Mycenax Biotech, Prestige Biologics, Binex, Champions Oncology, Frontage Laboratories, Nanoform. |
| What is the current market cap of Selvita? | Selvita's current market cap is $161M. |
| What is the current revenue of Selvita? | Selvita's last 12 months revenue is $104M. |
| What is the current revenue growth of Selvita? | Selvita revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Selvita? | Current revenue multiple of Selvita is 1.9x. |
| Is Selvita profitable? | Yes, Selvita is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Selvita? | Selvita's last 12 months EBITDA is $20M. |
| What is Selvita's EBITDA margin? | Selvita's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Selvita? | Current EBITDA multiple of Selvita is 10.0x. |
| What is the current FCF of Selvita? | Selvita's last 12 months FCF is $13M. |
| What is Selvita's FCF margin? | Selvita's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Selvita? | Current FCF multiple of Selvita is 15.8x. |
| How many companies Selvita has acquired to date? | As of May 2026, Selvita has acquired 1 company. |
| What was the largest acquisition by Selvita? | $6M acquisition of PozLab on 27th March 2024 was the largest M&A Selvita has done to date. |
| What companies Selvita acquired? | Selvita acquired PozLab. |
| In how many companies Selvita has invested to date? | Selvita hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Selvita
Lists including Selvita
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
